The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? (Q36709546)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 2007

Language	Label	Description	Also known as
English	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?	scientific article published on February 2007

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? (English)

1 reference

Europe PubMed Central

15 August 2017

metabolic syndrome

1 reference

based on heuristic

inferred from title

Dimitri P Mikhailidis

2

object named as

Dimitri P Mikhailidis

1 reference

Europe PubMed Central

15 August 2017

Evangelos N Liberopoulos

0 references

author name string

Asterios Karagiannis

1

1 reference

Europe PubMed Central

15 August 2017

Vasilios G Athyros

3

1 reference

Europe PubMed Central

15 August 2017

Anna I Kakafika

4

1 reference

Europe PubMed Central

15 August 2017

Konstantinos Tziomalos

5

1 reference

Europe PubMed Central

15 August 2017

Evangelos N Liberopoulos

6

1 reference

Europe PubMed Central

15 August 2017

Matilda Florentin

7

1 reference

Europe PubMed Central

15 August 2017

Moses Elisaf

8

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

1 February 2007

1 reference

Europe PubMed Central

15 August 2017

Expert Opinion on Therapeutic Targets

1 reference

Europe PubMed Central

15 August 2017

11

1 reference

Europe PubMed Central

15 August 2017

191-205

1 reference

Europe PubMed Central

15 August 2017

2

1 reference

Europe PubMed Central

15 August 2017

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Dyslipidaemia, hypercoagulability and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevention and treatment of the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Obesity, Metabolic Syndrome, and Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin signalling and the regulation of glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Adverse endothelial function and the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Role of insulin resistance in the genesis of sodium sensitivity in essential hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Serum-insulin in essential hypertension and in peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin and blood pressure among healthy children. Cardiovascular risk in young Finns

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin causes endothelial dysfunction in humans: sites and mechanisms.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Epidemic Obesity and the Metabolic Syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Diagnosis and management of the metabolic syndrome in obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Blood pressure and adiposity in children and adolescents.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Secular blood pressure trends in normotensive persons: the Framingham Study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Body weight, weight change, and risk for hypertension in women

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Is there a rationale for angiotensin blockade in the management of obesity hypertension?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Mechanisms of hypertension and kidney disease in obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Human adipocytes secrete mineralocorticoid-releasing factors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Obesity-related hypertension: is there a role for selective leptin resistance?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Splanchnic lipolysis in human obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Weight change is associated with change in arterial stiffness among healthy young adults

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Cross-talk between the insulin and angiotensin signaling systems

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Adverse prognostic significance of new diabetes in treated hypertensive subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Uric acid: role in cardiovascular disease and effects of losartan

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

A causal role for uric acid in fructose-induced metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Uric acid levels and vascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of losartan/diuretic combination treatment on serum uric acid levels in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Clinical profile of eprosartan

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Elevation of sympathetic activity by eprosartan in young male subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

New treatment strategies for patients with hypertension and insulin resistance

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Possible beneficial effect of telmisartan on glycemic control in diabetic subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect of ramipril on the incidence of diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The ONTARGET/TRANSCEND Trial Programme: baseline data

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The DREAM trial – Authors' reply

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Identifiers

10.1517/14728222.11.2.191

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36709546&oldid=1516413125"